Susan Nahirniak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Susan Nahirniak has a total of 318 co-authors. Here are the top co-authors by number of shared publications:
- Simon J. Stanworth
NHS Blood and Transplant Bristol UK
4 shared publications Bruce Ritchie
Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
3 shared publicationsG. Clarke
The Department of Laboratory Medicine and Pathology, Alberta Health Services, Edmonton, AB, Canada
3 shared publicationsGwen Clarke
Transfusion Medicine, Edmonton Zone; Alberta Health Services; Edmonton Alberta Canada
3 shared publications- Miquel Lozano
Apheresis Unit, Department of Hemotherapy and Hemostasis, Hospital Clínic Barcelona , Catalonia
3 shared publications - Sam Schulman
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
3 shared publications
Latest Publications
- 15 May 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (20) , 2293-2302
How I treat patients who are refractory to platelet transfusions
Patients with thrombocytopenia requiring ongoing platelet transfusion support may develop inadequate platelet count increments, referred to as platelet refractoriness (PR), which further complicates their care. The underlying etiologies of PR can be broadly divided into immune and nonimmune causes. A high index of suspicion is required to initiate testing for alloimmunization, and the leading culprit in immune PR is the development of class I HLA antibodies. The approach to diagnosis of immune PR has changed over recent years with new technologies, but questions regarding the clinical significance and interpretation of these methods have not been conclusively answered. The provision of HLA-matched platelets requires close and timely coordination between transfusion services and clinical teams; however, the true impact of their provision on clinical outcomes is not clear. This paper reviews diagnostic and management challenges, appraises the existing data available to support treatment options, and identifies research gaps.
- 15 May 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (20) , 2293-2302
How I treat patients who are refractory to platelet transfusions
Patients with thrombocytopenia requiring ongoing platelet transfusion support may develop inadequate platelet count increments, referred to as platelet refractoriness (PR), which further complicates their care. The underlying etiologies of PR can be broadly divided into immune and nonimmune causes. A high index of suspicion is required to initiate testing for alloimmunization, and the leading culprit in immune PR is the development of class I HLA antibodies. The approach to diagnosis of immune PR has changed over recent years with new technologies, but questions regarding the clinical significance and interpretation of these methods have not been conclusively answered. The provision of HLA-matched platelets requires close and timely coordination between transfusion services and clinical teams; however, the true impact of their provision on clinical outcomes is not clear. This paper reviews diagnostic and management challenges, appraises the existing data available to support treatment options, and identifies research gaps.
- Open Access
- 3 January 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (3) , e14459
Successful ABO incompatible heart transplantation after desensitization therapy in an older child
Background: ABO‐incompatible heart transplantation (HTx) has become a standard procedure for children below 2 years of age due to an immunologically immature immune system and associated low isohemagglutinin titers.Methods: We report a case of an ABO‐incompatible HTx (recipient blood group O, donor blood group A) at the age of 5 years and 11 months with a fully matured immune system and previously high isohemagglutinin titers that diminished as a result of human leucocyte antigen (HLA) desensitization therapy with rituximab and immunoglobulins.Results: The anti‐A titer at the time of HTx was 1:16 with post‐transplant isoagglutinin titers never exceeding 1:4 without any signs of rejection with now 3 years of post‐HTx follow‐up.Conclusions: ABO isohemagglutinin titers should be routinely assessed in children undergoing desensitization therapy since ABOi transplantation can be considered in selected cases to expand the donor pool with the option of crossing the ABO barrier to find a better‐matched allograft.
- 3 January 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (3) , e14459
Open AccessSuccessful ABO incompatible heart transplantation after desensitization therapy in an older child
Background: ABO‐incompatible heart transplantation (HTx) has become a standard procedure for children below 2 years of age due to an immunologically immature immune system and associated low isohemagglutinin titers.Methods: We report a case of an ABO‐incompatible HTx (recipient blood group O, donor blood group A) at the age of 5 years and 11 months with a fully matured immune system and previously high isohemagglutinin titers that diminished as a result of human leucocyte antigen (HLA) desensitization therapy with rituximab and immunoglobulins.Results: The anti‐A titer at the time of HTx was 1:16 with post‐transplant isoagglutinin titers never exceeding 1:4 without any signs of rejection with now 3 years of post‐HTx follow‐up.Conclusions: ABO isohemagglutinin titers should be routinely assessed in children undergoing desensitization therapy since ABOi transplantation can be considered in selected cases to expand the donor pool with the option of crossing the ABO barrier to find a better‐matched allograft.
- Open Access
- 1 April 2021
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 40 (4) , S229
ABO-Incompatible Heart Transplantation in Older Children Using Immune Modulation
- 1 April 2021
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 40 (4) , S229
Open AccessABO-Incompatible Heart Transplantation in Older Children Using Immune Modulation
- Open Access
- 19 May 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (12) , 3509-3519
Transfusion-transmitted and community-acquired cytomegalovirus infection in seronegative solid organ transplant recipients receiving seronegative donor organs
- 19 May 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 20 (12) , 3509-3519
Open AccessTransfusion-transmitted and community-acquired cytomegalovirus infection in seronegative solid organ transplant recipients receiving seronegative donor organs
- 12 November 2018
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 118 (12) , 2188
Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
In the Original Article by Schulman et al. “Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study” (Thromb Haemost 2018;118:842–851) after publication of the article it has come to the corresponding author's attention that the author affiliations were mixed up. The amended author affiliations are as above.
- 12 November 2018
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 118 (12) , 2188
Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
In the Original Article by Schulman et al. “Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study” (Thromb Haemost 2018;118:842–851) after publication of the article it has come to the corresponding author's attention that the author affiliations were mixed up. The amended author affiliations are as above.
- 1 September 2018
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 19 (9) , 846-853
Albumin 5% Versus Crystalloids for Fluid Resuscitation in Children After Cardiac Surgery*
Objectives: To determine the clinical benefit of using colloids versus crystalloids for volume resuscitation in children admitted after cardiac surgery. Design: Retrospective pre-/postintervention cohort study. Setting: Stollery Children’s Hospital tertiary care pediatric cardiac ICU. Patients: Children admitted to the pediatric cardiac ICU after cardiac surgery. Interventions: Fluid resuscitation policy change in which crystalloids replaced albumin 5% as the primary fluid strategy for resuscitation after cardiac surgery. Measurements and Main Results: Children who underwent cardiac surgery in the 6 months prior to the policy change (5% albumin group) were compared with children admitted during the 6 months after (crystalloid group). Demographic, perioperative, and outcome variables (fluid intake days 1–4 postoperative, vasoactive therapy, blood products, time to negative fluid balance, renal replacement therapies, mechanical ventilation, pediatric cardiac ICU, and length of stay) were collected. Data were analyzed using linear and logistic multivariate analysis. The study included 360 children. There was no association between fluid group and fluid intake (mL/kg) on day 1 postoperatively (coefficient, 2.84; 95% CI, 5.37–11.05; p = 0.497). However, crystalloid group was associated with significantly less fluid intake on day 2 (coefficient, –12.8; 95% CI, –22.0 to –3.65; p = 0.006), day 3 (coefficient, –14.9; 95% CI, –24.3 to –5.57; p = 0.002), and on the first 48 hours postoperative (coefficient, 10.1; 95% CI, –27.9 to –1.29; p = 0.032). Pediatric cardiac ICU stay (coefficient, –1.29; 95% CI, –2.50 to –0.08; p = 0.036) was shorter for the crystalloid group. There were no significant differences in the time to negative balance, need for renal replacement therapy, mechanical ventilation days, hospital stay, or pediatric cardiac ICU survival. Conclusions: In our study, the use of albumin 5% for resuscitation after cardiac surgery was not associated with less fluid intake but rather the opposite. Albumin administration did not provide measured clinical benefit while exposing children to side effects and generating higher costs to the healthcare system.
- 1 September 2018
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 19 (9) , 846-853
Albumin 5% Versus Crystalloids for Fluid Resuscitation in Children After Cardiac Surgery*
Objectives: To determine the clinical benefit of using colloids versus crystalloids for volume resuscitation in children admitted after cardiac surgery. Design: Retrospective pre-/postintervention cohort study. Setting: Stollery Children’s Hospital tertiary care pediatric cardiac ICU. Patients: Children admitted to the pediatric cardiac ICU after cardiac surgery. Interventions: Fluid resuscitation policy change in which crystalloids replaced albumin 5% as the primary fluid strategy for resuscitation after cardiac surgery. Measurements and Main Results: Children who underwent cardiac surgery in the 6 months prior to the policy change (5% albumin group) were compared with children admitted during the 6 months after (crystalloid group). Demographic, perioperative, and outcome variables (fluid intake days 1–4 postoperative, vasoactive therapy, blood products, time to negative fluid balance, renal replacement therapies, mechanical ventilation, pediatric cardiac ICU, and length of stay) were collected. Data were analyzed using linear and logistic multivariate analysis. The study included 360 children. There was no association between fluid group and fluid intake (mL/kg) on day 1 postoperatively (coefficient, 2.84; 95% CI, 5.37–11.05; p = 0.497). However, crystalloid group was associated with significantly less fluid intake on day 2 (coefficient, –12.8; 95% CI, –22.0 to –3.65; p = 0.006), day 3 (coefficient, –14.9; 95% CI, –24.3 to –5.57; p = 0.002), and on the first 48 hours postoperative (coefficient, 10.1; 95% CI, –27.9 to –1.29; p = 0.032). Pediatric cardiac ICU stay (coefficient, –1.29; 95% CI, –2.50 to –0.08; p = 0.036) was shorter for the crystalloid group. There were no significant differences in the time to negative balance, need for renal replacement therapy, mechanical ventilation days, hospital stay, or pediatric cardiac ICU survival. Conclusions: In our study, the use of albumin 5% for resuscitation after cardiac surgery was not associated with less fluid intake but rather the opposite. Albumin administration did not provide measured clinical benefit while exposing children to side effects and generating higher costs to the healthcare system.
- 1 July 2018
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 32 (3) , 135-143
Quality of Evidence-Based Guidelines for Transfusion of Red Blood Cells and Plasma: A Systematic Review
- 1 July 2018
- Published by Elsevier in Transfusion Medicine Reviews
- Vol. 32 (3) , 135-143
Quality of Evidence-Based Guidelines for Transfusion of Red Blood Cells and Plasma: A Systematic Review
- Top Cited Papers
- 21 March 2018
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 118 (05) , 842-851
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
Oral factor Xa inhibitors are increasingly used for anticoagulation, but there is no approved reversal agent. Prothrombin complex concentrate (PCC) for the management of Xa-inhibitor–associated bleeding has been described in small case series and one cohort study. Patients on apixaban or rivaroxaban, suffering a major bleed, were treated at nine Canadian hospitals as per existing hospital protocol with a fixed dose of PCC 2,000 units and subsequently recruited for a 30-day follow-up. The treating physician evaluated the haemostatic effectiveness as observed during the first day as good, moderate or poor/none, using an assessment guide. Safety outcomes were thromboembolism or death. We recruited 66 patients with major bleeding who were treated with PCC and who were receiving rivaroxaban (56%) or apixaban (44%). The effectiveness was assessed as good in 65% (95% confidence interval [CI], 53–77), moderate in 20% (95% CI, 10–30) and poor/none in 15% (95% CI, 6–24). For the 36 patients with intracranial haemorrhage, the corresponding ratings were 67, 17 and 17%, and for 16 patients with gastrointestinal bleeding they were 69, 12 and 19%, respectively. There were nine deaths (14%) by 30 days, and five (8%) major thromboembolic events. In a post hoc analysis, according to International Society on Thrombosis and Haemostasis criteria, reversal was effective in 68% and ineffective in 32%. For major bleeding associated with oral Xa inhibitors, PCC may have a beneficial effect. The risk of thromboembolism after reversal of anticoagulation in patients with a prothrombotic background has to be taken into account. S. Schulman, B. Ritchie and M. Carrier conceived and designed the study; S. Schulman analysed and interpreted the data; all authors provided study patients, collected data, wrote and gave final approval of the manuscript. * The investigators are listed in Appendix A.
- 21 March 2018
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 118 (05) , 842-851
Top Cited PapersProthrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study
Oral factor Xa inhibitors are increasingly used for anticoagulation, but there is no approved reversal agent. Prothrombin complex concentrate (PCC) for the management of Xa-inhibitor–associated bleeding has been described in small case series and one cohort study. Patients on apixaban or rivaroxaban, suffering a major bleed, were treated at nine Canadian hospitals as per existing hospital protocol with a fixed dose of PCC 2,000 units and subsequently recruited for a 30-day follow-up. The treating physician evaluated the haemostatic effectiveness as observed during the first day as good, moderate or poor/none, using an assessment guide. Safety outcomes were thromboembolism or death. We recruited 66 patients with major bleeding who were treated with PCC and who were receiving rivaroxaban (56%) or apixaban (44%). The effectiveness was assessed as good in 65% (95% confidence interval [CI], 53–77), moderate in 20% (95% CI, 10–30) and poor/none in 15% (95% CI, 6–24). For the 36 patients with intracranial haemorrhage, the corresponding ratings were 67, 17 and 17%, and for 16 patients with gastrointestinal bleeding they were 69, 12 and 19%, respectively. There were nine deaths (14%) by 30 days, and five (8%) major thromboembolic events. In a post hoc analysis, according to International Society on Thrombosis and Haemostasis criteria, reversal was effective in 68% and ineffective in 32%. For major bleeding associated with oral Xa inhibitors, PCC may have a beneficial effect. The risk of thromboembolism after reversal of anticoagulation in patients with a prothrombotic background has to be taken into account. S. Schulman, B. Ritchie and M. Carrier conceived and designed the study; S. Schulman analysed and interpreted the data; all authors provided study patients, collected data, wrote and gave final approval of the manuscript. * The investigators are listed in Appendix A.
- 26 September 2017
- Published by Wiley in ISBT Science Series
- Vol. 12 (4) , 418-421
Hospital transfusion medicine committees – problems and pitfalls
Hospital Transfusion Medicine Committees (TMCs) are multidisciplinary committees that provide oversight of a variety of clinical activities as they pertain to transfusion medicine and patient care in hospital environments. Across the globe, there are many different standards that provide guidance on the goals, structure and function of hospital transfusion medicine committees but these are not always implemented in the same manner. This review will highlight some of these standards and undertake a high‐level review of the similarities and differences. Awareness of common barriers to success for TMCs will allow strategies to be developed locally to ensure that the TMC functions in the most effective manner to provide high‐quality transfusion medicine care to patients.
- 26 September 2017
- Published by Wiley in ISBT Science Series
- Vol. 12 (4) , 418-421
Hospital transfusion medicine committees – problems and pitfalls
Hospital Transfusion Medicine Committees (TMCs) are multidisciplinary committees that provide oversight of a variety of clinical activities as they pertain to transfusion medicine and patient care in hospital environments. Across the globe, there are many different standards that provide guidance on the goals, structure and function of hospital transfusion medicine committees but these are not always implemented in the same manner. This review will highlight some of these standards and undertake a high‐level review of the similarities and differences. Awareness of common barriers to success for TMCs will allow strategies to be developed locally to ensure that the TMC functions in the most effective manner to provide high‐quality transfusion medicine care to patients.